Endocrine Abstracts

Objectives: The aim of the audit was to determine how our current clinical practice differs from that of the national standard set out in the UK by NICE guidance CG87 in regards to the use of exenatide.Material and methods: We measured weight and HbA1c at baseline and then again at 6 months from the date exenatide was started. The UK NICE guidelines recommends exenatide should only be considered in patients with a BMI≥35.0 kg/m2 with a H...